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Abstract: Despite excellent oncologic outcomes, the management of localized prostate
cancer remains complex and is dependent on multiple factors, including patient life expec
tancy, medical comorbidities, tumor characteristics, and genetic risk factors. Decades of
iterative clinical trials have improved the optimization and utilization of surgical and radia
tion-based modalities, as well as their combinatorial use with anti-androgen and systemic
therapies. While cure rates are high and converging on equivalent disease control should an
upfront surgical or radiotherapeutic approach be optimized, the long-term side effects of
surgical and radiation-based treatments can differ significantly in nature. Decisions regarding
the selection of therapy are therefore best made in an informed and shared medical decisionmaking process between clinician and patient with respect to cancer control as well as
adverse effects. We outline in this narrative review an understanding regarding implications
of surgical and radiation treatment on quality of life after treatment, and how these data may
be considered in the context of advising patients regarding the selection of therapy. This
narrative review largely focuses on the quality of life data obtained from prospective
randomized trials of men treated for prostate cancer. We believe this provides the best
assessment of the quality of life and can be used to inform patients when making treatment
decisions.
Keywords: prostate cancer, radical prostatectomy, radiation therapy, quality of life, toxicity
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Estimated 191,930 new cases of prostate cancer will be diagnosed in the United
States in 2020, accounting for 21% of new cancer cases in men.1 Overall prognosis,
especially in the setting of localized disease, is extremely good with five-year
relative survival greater than 98% for all races between 2009 and 2015. In general,
men who are older and have very low-risk prostate cancer may not benefit from
active intervention and instead may choose a strategy of watchful waiting2
(Table 1). For men who have longer life expectancy and low-risk disease, active
surveillance, radical prostatectomy (RP), external beam radiation (XRT), and bra
chytherapy (BT) are all options supported by the National Comprehensive Cancer
Network (NCCN) guidelines.3–7 With regard to the radiation treatment course,
conventional fractionation, hypofractionation, and stereotactic body radiotherapy
(SBRT) may all be considered options based upon individual risk assessment, as
well as tumor and treatment characteristics.8–12 NCCN favorable intermediate-risk
disease (<50% of cores positive, no Gleason Grade Group 3 or higher histology,
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Table 1 Treatment Selection for Localized Prostate Cancer, Stratified by Risk Group
Disease Group

Treatment Modalities

Low-Risk

If expected patient survival ≥ 10 years, active surveillance, external beam radiation (standard fractionation,
hypofractionation, or SBRT), brachytherapy (HDR or LDR), and radical prostatectomy are all options; if < 10 years,
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observation is recommended
Favorable Intermediate-

If expected patient survival ≥ 10 years, active surveillance, external beam radiation, brachytherapy, and radical

Risk

prostatectomy are all options; if < 10 years, observation, external beam radiation, or brachytherapy is recommended

Unfavorable

If expected patient survival ≥ 10 years, radical prostatectomy, external beam radiation with 4–6 months of ADT,

Intermediate-Risk

external beam radiation and brachytherapy boost and 4–6 months of ADT are all options; if < 10 years, observation,
external beam radiation with 4–6 months ADT, and external beam radiotherapy and brachytherapy boost and 4–6
months ADT are all options

High-Risk

brachytherapy boost and 18–36 months of ADT, and radical prostatectomy are all options; if ≤ 5 years and
asymptomatic, observation, external beam radiation and ADT are all options
Adjuvant/Salvage

If adverse features (positive margins, seminal vesicle involvement, and/or extraprostatic extension), consider adjuvant
external beam radiation; otherwise, close monitoring with external beam radiation and 6–24 months of ADT
recommended if clinical or biochemical evidence of failure

only one intermediate-risk factor) has a treatment algo
rithm that is similar to low-risk disease.13 Unfavorable
intermediate-risk and high-risk diseases typically require
the addition of androgen deprivation therapy (ADT), as
well as potentially a brachytherapy boost, to external beam
radiotherapy.6,14–20 Regarding length of ADT, unfavorable
intermediate-risk disease and high-risk disease typically
require 4–6 months and 18–36 months, respectively, with
currently less level 1 data regarding justifying the optimal
length of ADT in the setting of brachytherapy boost.6,21–25
The addition of systemic therapy, e.g. docetaxel, to radia
tion has been historically more controversial and indivi
dualized in the context of high-risk, localized disease,
though recent data from the GETUG 12 trial as well as
RTOG 0521 have suggested superior 8-year relapse-free
survival and 4-year overall survival, respectively.26,27
Given the limited data, however, the addition of docetaxel
to ADT plus XRT in high- or very high-risk prostate
cancer is not categorically recommended as of NCCN
Version 2.2020 until longer follow-up demonstrates com
parable success of salvage treatments and rates of longterm adverse effects.
External beam radiation often incorporates pelvic nodal
treatment when there is a threshold risk of lymph node
involvement, e.g. 15% or higher28,29 (Figure 1). This risk
is estimated based on clinical factors such as Gleason
Score (GS) and Prostate Specific Antigen (PSA), often
with the assistance of a nomogram. RTOG 0924 trial is
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underway to provide further insight into the definitive RT
setting. Postoperatively, XRT and ADT still may be a
requirement in the adjuvant setting depending on factors
such as lymph node involvement, positive margins, extra
prostatic extension, and seminal vesicle involvement.30–34
If adjuvant treatment is not pursued based on favorable
pathology, salvage radiation to the disease bed or pelvis, as
well as ADT, still is required if there is clinical or bio
chemical evidence of failure,35,36 with the extent of nodal
treatment additionally under investigation in the salvage
setting.37
The first generation of meta-analyses utilizing obser
vational data compared surgical and radiation-based
modalities across all risk groups of localized disease
with regard to overall mortality (OM) and prostate can
cer-specific mortality (PCM) hazard ratios, the most well
known of which found OM and PCM benefits to upfront
surgery across all groups.38 Additional efforts found that
controlling for quality of ADT, adequate radiation dose,
and overall compliance with modern NCCN standard-ofcare diminished these differences.39,40 There is even a
suggestion of improved PCM for RT-based modalities
compared with RP in the setting of Gleason 9–10 disease
when BT is used with XRT, though there are limited
observational data available to answer this question.41–
44
There is some evidence that this advantage for bra
chytherapy boost diminishes in the setting of RP plus
adjuvant RT.43,44 Should these data prove verifiable
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Figure 1 Surgical and Radiotherapeutic Approaches in the Treatment of Prostate Cancer. (A) pre- and post-prostatectomy anatomy with retropubic and perineal surgical
approaches. (B) microsurgical anatomy at risk for injury with retropubic and surgical approaches. (C) clinical target volumes (CTV) for radiotherapy for intact prostate
treated definitively with external beam radiotherapy (XRT). When indicated pelvic lymph node fields are added, increasing the potential for gastrointestinal toxicity. (D) CTV
for radiotherapy for prostate fossa treated adjuvantly or in salvage cases. The utility of lymph node coverage in this setting is the subject of clinical investigation. (E) CTV for
low-dose-rate brachytherapy with or without XRT treatment. High-dose-rate techniques are available using temporary catheter-based placement of an Ir-192 source with
established fractionation schedules and fewer post-treatment radiation precautions.

with prospective data, there may be a subset of patients
with Gleason 9–10 or other high-risk diseases for which a
discussion of treatment options may converge on XRT
+BT with ADT versus RP with a very strong possibility
of requiring adjuvant RT. Counseling patients regarding
the burden of GU-related toxicity associated with BTboost is substantially different if the pre-procedural prob
ability is high that adverse features will prompt adjuvant
radiation to the prostatic fossa and possibility pelvic
lymph nodes.

Research and Reports in Urology 2020:12

Given the high rates of success for oncologic out
comes as well as more robust algorithms to achieve
similar oncologic outcomes with upfront RP or RT,
there is a need to better understand the toxicities of
various treatment modalities and how they affect patient
quality of life. To help providers with this important
conversation, we have provided a narrative review of
the data involving treatment-related toxicity and poten
tial interventions to ameliorate toxicity during and after
treatment.
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Methods
We performed a search of the PubMed database to identify
pertinent articles that included quality of life assessments
relating to the treatment of prostate cancer and common
treatment modalities including RP, XRT, BT, and ADT.
The search focused on randomized clinical trials compar
ing treatment modalities for prostate cancer that included
quality of life metrics. In addition to database searches,
hand searches were also conducted based on expert opi
nion and author consensus. Studies including intraopera
tive fresh-frozen pathologic analysis of margins to
improve nerve sparing during RP or injection of hydrogel
spacers to improve rectal sparing during RT were not
included, given their relative novelty and lack of rando
mized data comparing surgical and radiotherapeutic out
comes. Searches of published abstracts were also included
in the formation of the manuscript when full articles were
not available. Finally, the manuscript and reference list
were evaluated and approved by all authors for inclusion
in the current publication.

Technical Approaches for Surgery
and Radiation
In general, there are two common approaches to RP, one
which employs a retropubic approach, in which the pros
tate is removed through an incision in the wall of the
abdomen, and the other a perineal approach, in which the
incision is made in the area between the scrotum and
anus45 (Figure 1). Retropubic prostatectomy was consid
ered the gold standard since the early 1980s due to the
ability to access and remove pelvic lymph nodes, as well
as spare cavernosal nerves. The dorsal vein complex is at
risk, however, and blood loss requiring transfusions has
been shown to be a risk of this approach.46 Since many
patients at low risk for metastasis do not require extensive
pelvic lymph node dissection, a perineal prostatectomy is
an alternative approach and often causes less blood loss by
avoiding the dorsal vein complex.47 Regarding robotic
prostatectomy, studies have shown lower estimated blood
loss, shorter hospital stays, a lower incidence of bladder
neck contractures/anastomotic strictures, and lower intrao
perative adverse event.48 However, there is a lack of
randomized, long-term studies that compare functional
and oncologic outcomes between open and robotic
approaches.
Modern
robotic
techniques
(e.g.,
NeuroSAFE) continue to evolve, including intraoperative
fresh-frozen section analysis of prostate margins to assess
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and optimize oncologic resection while maintaining func
tional outcomes, with randomized trials underway.49
Overall, most patients who opt for definitive management
with prostatectomy can initially avoid androgen depriva
tion therapy and its associated effects on quality of
life (QOL).
With regard to radiation, there are multiple techniques
including XRT and BT. Dose escalation to 74–81 Gy has
been shown to improve biochemical failure-free survival
over lower doses; however, no overall survival benefit has
been shown with these increasing doses over lower doses
(~70 Gy).8,50–53 Hypofractionation, which typically uses
60–70 Gy over a shorter time interval, has demonstrated
noninferiority to standard fractionation for low, intermedi
ate, and high-risk disease; SBRT, a form of ultra-hypo
fractionated RT using image guidance and highly
conformal techniques, has appeared safe at currently avail
able follow-up and has allowed select patients to finish
radiotherapy in 2 weeks.54 Treatment to the prostate in the
definitive setting is delivered to the organ with an addi
tional 5–10 mm margin to account for organ motion or
setup uncertainties, with the extent of coverage of the
seminal vesicles informed by risk group and several inten
sity-modulated radiotherapy protocols available to guide
planning.55 Surrounding organs, such as the bladder, rec
tum, penile bulb, and bilateral femora, are delineated dur
ing planning as they receive radiation dose during
treatment.56 In the adjuvant and salvage setting, the pros
tate fossa is typically defined as at least 2 cm above the
pubic symphysis to the top of the penile bulb, including
surgical clips and seminal vesicle remnants if involvement
is detected, with an additional 8–15 mm margin added due
to setup uncertainty and movement.57 The decision to treat
lymph nodes significantly affects the anticipated exposure
to the rectum and surrounding organs, as does the amount
of margin necessary in the setting of chosen technique and
image guidance. Rectal spacers are often used to mitigate
short and late-term side effects of radiation therapy,58
though these techniques have not yet been reflected in
randomized data comparing the quality of life following
surgery versus radiation.

Limited Conclusions from
Retrospective Observational Data
The reference standard in determining the impact any
treatment modality has on an individual patient is the use
of patient-reported outcomes (PROs), as they represent the

Research and Reports in Urology 2020:12

Research and Reports in Urology downloaded from https://www.dovepress.com/ by 147.140.233.14 on 22-Dec-2020
For personal use only.

Dovepress

patients’ perspective on how their quality of life has chan
ged in contrast to physician-graded toxicity.59 Reportable
tools and assessments have been developed and increas
ingly deployed across observational and prospective
research.60 Given the sample sizes and amount of followup required to measure differences in both frequent and
infrequent morbidity endpoints, it has been tempting to use
prostate cancer registries to answer questions regarding the
differential incidence of various toxicities between
approaches using upfront RP and RT. These cancer regis
tries have tracked different levels of detail concerning
treatment, with several important features such as ADT
use, RT dose, and radiation technique inconsistently
tracked and reported.61 Moreover, the use of these regis
tries has more categorially been challenged by data sug
gesting that the systematic concordance between hazard
ratios generated from observational studies and corre
sponding randomized controlled trials is little better than
if left to chance.62
Despite these caveats, multiple efforts have attempted
to leverage large sample size and registry data to answer
quality of life questions following prostate cancer
treatment.63–66 The Prostate Cancer Outcomes Study uti
lized six Surveillance, Epidemiology and End Results
registries to recruit 3533 men, 1655 of whom had surgery
or radiotherapy for localized disease within a year of
diagnosis with follow-up surveys at 2 and 5 years.63 Men
following surgery demonstrated more urinary incontinence
and erectile dysfunction, while those receiving radiother
apy predominantly demonstrated GI symptoms including
bowel urgency. These symptoms were noted at the early
time points of 2 and 5 years, though all differences save
for bowel symptoms were insignificant by year 15. Most
of these men notably received an older generation of
radiation therapy, with inconsistent utilization of ADT,
though more modern data have been utilized to replicate
these findings.64,65

Quality of Life Outcomes from
Randomized Data and Prospective
Cohort Studies
Prospective randomized controlled trials (PRTs) are con
sidered by many as the reference standard for clinical
studies as they allow for equal distribution of both mea
sured and unmeasured covariates across strata of control
and exposure groups, create a baseline timepoint for
cohort evaluation and lend to easy statistical analysis. It
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has become increasingly important to also assess func
tional outcomes when designing and conducting clinical
trials in men with prostate cancer due to the improved
understanding of converging oncologic outcomes with
surgery and radiation. Accordingly, it would reason that
PROs incorporated into prospective randomized studies of
men treated for prostate cancer would serve as the highest
level of evidence to directly compare treatment-related
toxicity and QOL. Despite this, there remains a paucity
of PROs obtained from RCT’s to help guide physicians
and patients on expected toxicities when selecting an
appropriate treatment approach in the setting of multidis
ciplinary care.
The quality of life companion article of men enrolled
in the Prostate Testing for Cancer and Treatment (ProtecT)
trial may provide the best prospective QOL data in men
with localized prostate cancer following treatment with
one of the most commonly used methods: surgery, radio
therapy or active monitoring.67 Briefly, the ProtecT study
was a multicenter, randomized clinical trial of men with
screening-detected prostate cancer who were randomized
in a 1:1:1 fashion to either radical prostatectomy, active
monitoring or radiotherapy with 4 months of ADT.4 In all,
545 men were randomized to active monitoring, 553 men
to radical prostatectomy and 545 men to radiotherapy +
ADT. After 10 years of follow-up, the authors noted no
difference in PCM, though the measured PCM remained
low in all cohorts, with only 17 prostate cancer-specific
deaths.4 It is important to note that most men enrolled in
the ProtecT study had low-risk disease and further extra
polation of this study to cohorts of men with high-risk
disease is cautioned, a risk category that will likely need to
wait for the results of SPCG-15 for randomized data.68
In the ProtecT QOL study by Donovan et al, 1643 men
enrolled on ProtecT completed validated questionnaires
before diagnosis, at 6 and 12 months after randomization,
and annually thereafter.67 The companion study was
designed to provide a direct comparison of the QOL of
men treated uniformly with either radiotherapy/ADT, radi
cal prostatectomy, or active monitoring. The study
included validated measures that assessed multiple
domains including urinary, bowel, sexual function, and
specific effects on quality of life, anxiety, depression and
general health. The published report included 5 years of
follow-up data on cancer-related quality of life and 6 years
of follow-up data on additional endpoints. The authors
analyzed the data according to the intention-to-treat prin
ciple based upon patient randomization into the treatment
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groups of the ProtecT trial. Overall, radical prostatectomy
was associated with worse outcomes in erectile dysfunc
tion and urinary incontinence compared with radiotherapy
and 4 months of ADT. Conversely, radiotherapy and ADT
were associated with significantly more bowel toxicity
(Table 2). Importantly, when assessing the entire cohort,
no significant differences were observed among any treat
ment group in general health-related, cancer-related qual
ity of life, depression or anxiety.67 Despite equivalence in
global health-related quality of life between treatment
modalities, the study does demonstrate that toxicity pro
files between radiotherapy and radical prostatectomy are
different. These data are useful when discussing with
patients. Overall, radiotherapy is more associated with
worsened bowel symptoms while prostatectomy is asso
ciated with worsening of urinary incontinence and erectile
dysfunction. To magnify this association, the authors
report that compared to the active monitoring group the
number needed to treat (NNT) to cause a single additional
case of erectile dysfunction at 2 years is 4 with radical
prostatectomy and 8 with radiotherapy, and the NNT to
cause a single additional case of urinary incontinence at 2
years is 5 for RP and 143 for RT. However, as follow-up
continued to 6 years the authors demonstrate that urinary
and sexual function had stabilized in the radiotherapy
group after improving for 2–3 years, while urinary and
sexual function declined over this time period in the active
monitoring group. As such, with this additional follow-up,
the authors conclude that men treated with either active
monitoring or radiotherapy with ADT had similar QOL
with respect to sexual function and urinary incontinence,
but these scores remained worse in men treated with
prostatectomy.
It is important to note that the ProtecT study used
modern approaches to surgery and thus may not be biased
by older surgical procedures. The authors note that the
majority of the 545 men randomized to radical prostatect
omy underwent an open retropubic, nerve-sparing proce
dure. This nerve-sparing approach would be expected to
reduce the rates of toxicities such as erectile dysfunction.
In the radiation arm, patients were treated with modern
dose-escalated prescriptions to 7400 cGy in 37 fractions
using three-dimensional conformal radiotherapy. While the
dose in this cohort reflects modern prescribing, newer
techniques such as intensity-modulated radiotherapy
(IMRT) or volumetric modulated arc therapy (VMAT)
are now more routinely used as they are associated with
fewer toxicities compared with 3D conformal radiation.69
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Despite this, the QOL data from the ProtecT study provide
high-quality evidence regarding the impact of modern
treatments for men with clinically localized prostate can
cer and can be used to guide physicians and patients when
considering treatment recommendations.
Another PRT comparing surgery vs radiotherapy with
PROs was conducted by Lennernas et al and included men
with locally advanced high-risk prostate cancer.70 This
study conducted in Sweden between 1996 and 2001
included 89 men and randomized them 1:1 to either radical
prostatectomy or radiotherapy consisting of 50 Gy external
beam radiotherapy with high-dose-rate brachytherapy
delivered in 2 separate fractions of 10 Gy each. All men
in the trial were also treated with 6 months of neoadjuvant
total androgen blockade. The primary outcome was the
difference in health-related quality of life (HRQoL) using
PROs. The study assessed self-reported HRQoL and
symptoms including urinary, bowel, and sexual function
prior to randomization and at 12 and 24 months following
randomization.70 The authors report that no discernible
differences in HRQoL or complications were demon
strated between the two treatment groups. One unique
aspect of the study is that all men were treated with total
androgen blockade. This allows for a better comparison
between the two treatment modalities of radiotherapy and
surgery without ADT confounding the radiotherapy arm. It
also compares what has been described as maximal radio
therapy with combination XRT and BT. Combination XRT
and BT have been shown to be associated with signifi
cantly more toxicity compared with XRT alone in prospec
tive studies.20 Given that all men were treated with ADT
and the radiotherapy arm received maximal radiotherapy,
this study provides data that even in high-risk men treated
aggressively, HRQoL as measured using PROs was similar
between treatment arms. This study is limited by the small
sample size and the nonconventional XRT dose given in
the radiation arm but still provides valuable information
using PROs from an RCT.
Another (pseudo)randomized study that published
PROs is the American College of Surgeons Oncology
Group Phase III Surgical Prostatectomy versus Interstitial
Radiation Intervention Trial (ACOSOG SPIRIT) by Crook
et al.71 This study compared RP with BT given definitively
as monotherapy. The trial was initially designed as a
randomized study but after slow accrual, the protocol
was amended to allow patients to choose or be randomized
to either RP or BT. Overall, the trial was terminated early
due to poor accrual but the authors report on HRQoL at 5
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years in patients enrolled on the trial. Overall, 168 men
were eligible for the toxicity analysis. In the entire cohort,
60.7% of men had BT (9.5% randomly assigned) and
39.3% of men had an RP (9.5% randomly assigned).
Five years after treatment all men were considered for
HRQoL evaluation using the cancer-specific 50-item
Expanded Prostate Cancer Index Composite, the Short
Form 12 Physical Component Score, and the Short Form
12 Mental Component Score. The overall response rate
was 88.4%. With a median follow-up of 5.2 years, the
authors report no differences between RP and BT in bowel
or hormonal domains. However, men treated with BT
scored better in urinary (91.8 v 88.1; p= 0.02) and sexual
(52.5 v 39.2; p= 0.001) domains as well as in patient
satisfaction (93.6 v 76.9; P <0.001).71 This study is limited
in its small sample size and largely non-random allocation
(only 19% of patients were randomly assigned) but pro
vides evidence that brachytherapy as monotherapy had
fewer adverse effects on HRQoL compared with
prostatectomy.
In a similar study, Giberti et al randomized 200 patients
to either radical retropubic prostatectomy or brachytherapy
as monotherapy and reported on oncological and func
tional outcomes.72 Men randomized to surgery underwent
bilateral nerve-sparing retropubic RP and standard lymph
node dissection and men randomized to BT received lowdose rate brachytherapy using I-125 seeds with a pre
scribed dose of D90 > 140 Gy. All men received ques
tionnaires including the International Prostate Symptom
Score (IPSS), International Index of Erectile Function
(IIEF), and the EORTC-QLQ-C30/PR25. Patients enrolled
in the study completed questionnaires before treatment as
well as every 3 months for the first year, every 6 months
for the second year, and then annually. In this study, the
authors report that RP was associated with worse erectile
function while BT was associated with worse urinary
voiding symptoms and bowel symptoms. Unlike the pre
viously discussed studies, the authors found no difference
in rates of urinary incontinence between study arms.
Finally, as demonstrated in several other PRTs with
PROs the authors report equivalent HRQoL between the
treatment arms.72
Although not a trial of radiation compared with pros
tatectomy, the Androgen Suppression Combined with
Elective Nodal and Dose Escalated Radiation Therapy
(ASCENDE-RT) trial was a PRT of men with localized
prostate cancer randomized to two different radiation
techniques.20 The study enrolled 398 men all of whom

Research and Reports in Urology 2020:12

Research and Reports in Urology downloaded from https://www.dovepress.com/ by 147.140.233.14 on 22-Dec-2020
For personal use only.

Dovepress

received 12 months of neoadjuvant ADT followed by XRT
to the prostate and elective nodes to a total dose of 46 Gy.
Men were randomized into one of the two radiation boost
arms: a standard dose-escalated XRT boost of an addi
tional 32 Gy to a total of 78 Gy, or an LDR brachytherapy
implant. The authors conclude that with 9 years of followup patients treated with an LDR brachytherapy implant
had improved biochemical progression-free survival.
However, compared with men who only received an
XRT boost, those who underwent LDR brachytherapy
had worse GU and GI toxicity as graded using the mod
ified Late Effects of Normal Tissue – Somatic, Objective,
Management, Analytic (LENT-SOMA) scale.73 Although
not an RCT between surgery and radiotherapy this study
provides evidence that XRT with ADT combined with an
LDR brachytherapy procedure has greater toxicity com
pared with the more commonly used approach of ADT
with dose-escalated external beam radiotherapy.
A recently published prospective cohort study by
Hoffman et al detailed the QOL impact of 1386 men
with favorable-risk localized prostate cancer treated with
either active surveillance (n=363), nerve-sparing prosta
tectomy (n=675), XRT alone (n=261) or low-dose rate
brachytherapy (n=87) and in men with unfavorable-risk
localized prostate cancer treated with RP (n=402) or
XRT + ADT (n=217).74 Patients reported their function
using the 26-item Expanded Prostate Index Composite 5
years after completing treatment. Among men with favor
able-risk disease, nerve-sparing prostatectomy was asso
ciated with worse urinary continence at 5 years and sexual
function at 3 years compared with active surveillance.
XRT was not associated with worse bowel, urinary or
sexual side effects compared with active surveillance at
any point during 5 years after treatment. In the unfavorable
risk subset, XRT + ADT was associated with worse bowel
function at 1 year, but better sexual function and incon
tinence compared with RP at each time point through 5
years. Overall, the results of the Hoffman analysis provide
evidence that XRT has a more favorable toxicity profile
compared with RP even when ADT is added in the unfa
vorable subgroup. Fortunately, none of the treatment
groups reported meaningful declines in the HRQOL
domains of physical function, emotional well-being, and
energy/fatigue scores.
As discussed, ADT is often added to XRT or BT in
unfavorable intermediate-risk and high-risk patient popu
lations. In addition to the toxicities caused by radiotherapy,
ADT introduces additional side effects. Several studies
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have shown that ADT independent of the effects of radio
therapy contributes to worse sexual function.75,76 In a
study by Gay et al the addition of neoadjuvant ADT to
XRT or BT was associated with worse QOL. Specifically,
the authors demonstrate that men on ADT had a decreased
ability to reach orgasm, had decreased quality of erections
and decreased sexual function.77 ADT also has metabolic
effects and can lead to increased weight gain and loss of
muscle mass. Unlike other toxicities associated with pros
tate cancer treatment, the side effects attributable to ADT
are often only transient and resolve after discontinuation
and normalization of testosterone levels.
Finally, in men who undergo RP but require postoperative radiotherapy either in the adjuvant or salvage
setting the addition of radiotherapy after prostatectomy has
been shown to worsen QOL. Jenkins et al studied 106 men
with PCa receiving post-prostatectomy radiotherapy and
assessed the QOL impact of radiotherapy using the
Expanded Prostate Cancer Index Composite (EPIC). The
authors demonstrate that post-prostatectomy radiotherapy
worsened urinary QOL with the most significant decline
noted in urinary incontinence.78 Other studies of postprostatectomy radiotherapy show only temporary worsen
ing of symptoms in urinary, sexual and bowel domains.79
Overall, studies seem to indicate a worse urinary function
in men who require post-prostatectomy radiotherapy.80
Given this information, it is important to consider these
implications when counseling men with high risk, high
volume disease (Gleason score 9–10) who would most
likely require adjuvant/salvage radiotherapy following
RP. In this setting, men may wish to consider definitive
XRT + ADT and forgo RP given the high chances of
requiring additional radiotherapy and the negative QOL
impacts demonstrated in men receiving both modalities of
treatment.

Managing Toxicities Associated with
Prostate Cancer Treatments
Given how successful treatment generally is for localized
prostate cancer, managing the adverse effects associated
with the various available treatment strategies is of para
mount importance in order to maximize patient quality-oflife. For example, it is well known that one of the most
bothersome toxicities associated with a surgical approach
to prostate cancer treatment is urinary incontinence, with
the risk of incontinence being highly dependent on both
age and surgical technique.81 Multiple strategies to aid
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men to recover urinary control have been investigated,
including both procedural and non-procedural techniques.
For example, placement of artificial urinary sphincters has
been shown to be a viable option, with the caveat that late
complications may occur which may require further pro
cedural intervention to remove the device.82 In addition,
transobturator sling suspension via placement of transob
turator tape has also been studied, resulting in a significant
rate of both complete cure of incontinence and decreased
pad usage.83 Finally, behavioral training with biofeedback
seems to be effective specifically for stress and urge
incontinence, but less so with patients who experience
continual leakage of urine following a prostatectomy.84
While incontinence following radiation treatment for
prostate cancer is a rare side effect, radiation may instead
cause hemorrhagic cystitis and radiation proctitis, both of
which also negatively impact patient quality of life.
Radiation cystitis can manifest itself both in the acute
post-treatment time period and multiple months to years
following completion of radiation treatment, and can vary
significantly in severity from a mild bleed up to significant
hemorrhage; as such, management strategies differ but
include cystoscopy with electrocoagulation of bleeding
areas, injection of botulinum toxin into the bladder wall,
and instillation of compounds such as formalin or prosta
glandins into the bladder itself.85 For radiation proctitis,
direct instillation of formalin during a sigmoidoscopy has
shown to be effective and often results in immediate
resolution of symptoms.86,87 Alternatively, argon plasma
coagulation, also performed during a flexible sigmoido
scopy, has also been demonstrated to be effective in both
reducing blood transfusion requirements related to radia
tion proctitis and improving other aspects of bowel func
tion such as resolving rectal urgency and stool
frequency.88 Radiofrequency ablation is an option for
those whose symptoms do not resolve with first or sec
ond-line interventions as well.89 For those who prefer a
less invasive therapy, short-chain fatty acid enemas were
superior to placebo in a prospective, randomized doubleblind trial examining the rapidity of healing of radiation
proctitis.90 Finally, hyperbaric oxygen has been shown to
be an effective treatment strategy for both patient com
plaints of hematuria related to radiation cystitis and rectal
bleeding or irritation from radiation proctitis following
radiation treatment for prostate cancer, but the use of this
technique is generally reserved after other lines of therapy
have been ineffective.91,92
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For many men undergoing treatment for prostate cancer,
maintenance of sexual function is an extremely important
consideration and component of their quality of life; unfor
tunately, sexual dysfunction is a common adverse effect of
both RT and RP, with similar rates for both therapies (parti
cularly now that surgical techniques have improved such
that nerve-sparing approaches are possible for localized
disease). Complicating studies on this subject is the fact
that with the exception of a recently validated standardized
questionnaire, the International Index of Erectile Function
(IIEF), defining terms such as “potency,” “satisfactory sex
ual function,” “sexual interest,” and “libido,” among others,
is dependent on individual interpretation.93 The first-line
treatment for erectile dysfunction is generally an oral phos
phodiesterase type 5 (PDE5) inhibitor, although specific
dosages and frequencies of administration vary.94 In fact,
prophylactic sildenafil citrate initiated before radiation ther
apy for prostate cancer and given continuously with the
intent of preserving erectile function until 6 months follow
ing completion of radiation therapy was demonstrated to
improve long-term sexual outcomes.95 Should patients not
respond to oral PDE5 agents, patients are generally offered
penile injections, penile implants, or vacuum erection
devices.96–98 Less invasive options such as exercise therapy
(with moderate to high intensity aerobic and resistance
training exercises) have also been shown to be effective,
even though they do not directly act on sexual organs, as
sexual function is intimately interwoven with mental health
and well-being.99 Finally, clear, constructive communica
tion between patients and their partners has been consis
tently shown to be one of the most important factors in
helping patients cope with sexual problems following pros
tate cancer treatment.100
Perhaps most importantly, comprehensive patient counsel
ing of the risks and benefits of each potential treatment option
is appropriate in men with localized prostate cancer. Many
tools are available to aid this process; for example, nomograms
have been developed to predict both acute and long-term rectal
toxicity associated with radiation therapy101–103 as well as
urinary adverse events.104 Involvement of a multidisciplinary
team of healthcare providers is essential such that the patient is
able to appreciate all available options for treatment, and
ultimately, although a consensus recommendation can be
made based on patient characteristics and/or disease involve
ment, patient participation with an informed final decision is
the most critical component to the management of patient
expectations regarding toxicity.105–107
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Conclusion
As discussed, there is a paucity of prospective randomized
data with PRO metrics for men treated with localized
prostate cancer. Based on the current review it appears
that prostatectomy is associated with higher rates of urin
ary incontinence and erectile dysfunction compared to
radiotherapy. Unlike surgery, radiotherapy appears to be
associated with worsening bowel function. However,
despite these differences, prospective evaluation seems to
indicate that global HRQoL does not differ in men by
treatment modality. Thus, an individualized discussion
that compares and contrasts different toxicity profiles of
each treatment modality may be the best approach clini
cally to encourage patient engagement in the shared med
ical decision-making process. There are myriad tools and
interventions, both procedural and non-procedural, avail
able to address the sequelae of an upfront RP or RT-based
approach. In the future, we believe that all men with
prostate cancer should have an informed discussion in
the setting of a multi-disciplinary setting to hear of all of
the information available before deciding on a treatment
approach.

Acknowledgments
The authors would like to thank Herbert Colunga for
artistic contributions related to Figure 1.

Disclosure
The authors report no conflicts of interest for this work.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J
Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
2. Albertsen PC. Observational studies and the natural history of screendetected prostate cancer. Curr Opin Urol. 2015;25(3):232–237.
doi:10.1097/MOU.0000000000000157
3. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy
or watchful waiting in early prostate cancer. N Engl J Med. 2014;370
(10):932–942. doi:10.1056/NEJMoa1311593
4. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after
monitoring, surgery, or radiotherapy for localized prostate cancer. N
Engl J Med. 2016;375(15):1415–1424. doi:10.1056/NEJMoa1606220
5. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy
versus observation for early prostate cancer. N Engl J Med. 2017;377
(2):132–142. doi:10.1056/NEJMoa1615869
6. Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version
2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr
Canc Netw. 2019;17(5):479–505. doi:10.6004/jnccn.2019.0023
7. Wallis CJD, Glaser A, Hu JC, et al. Survival and complications
following surgery and radiation for localized prostate cancer: an inter
national collaborative review. Eur Urol. 2018;73(1):11–20.
doi:10.1016/j.eururo.2017.05.055

Research and Reports in Urology 2020:12

Taylor et al
8. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus
hypofractionated high-dose intensity-modulated radiotherapy for
prostate cancer: 5-year outcomes of the randomised, non-inferior
ity, Phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–1060.
doi:10.1016/S1470-2045(16)30102-4
9. Catton CN, Lukka H, Gu C-S, et al. Randomized trial of a
hypofractionated radiation regimen for the treatment of localized
prostate cancer. J Clin Oncol. 2017;35(17):1884–1890.
doi:10.1200/JCO.2016.71.7397
10. Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III
noninferiority study comparing two radiotherapy fractionation
schedules in patients with low-risk prostate cancer. J Clin
Oncol. 2016;34(20):2325–2332. doi:10.1200/JCO.2016.67.0448
11. Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofrac
tionated versus conventionally fractionated radiotherapy for pros
tate cancer: 5-year outcomes of the HYPO-RT-PC randomised,
non-inferiority, phase 3 trial. Lancet London Engl. 2019;394
(10196):385–395. doi:10.1016/S0140-6736(19)31131-6
12. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy
for localized prostate cancer: pooled analysis from a multi-institu
tional consortium of prospective Phase II trials. Radiother Oncol.
2013;109(2):217–221. doi:10.1016/j.radonc.2013.08.030
13. Zumsteg ZS, Spratt DE, Pei I, et al. A new risk classification
system for therapeutic decision making with intermediate-risk
prostate cancer patients undergoing dose-escalated externalbeam radiation therapy. Eur Urol. 2013;64(6):895–902. doi:10.
1016/j.eururo.2013.03.033
14. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce
A, Kantoff PW. 6-month androgen suppression plus radiation
therapy vs radiation therapy alone for patients with clinically
localized prostate cancer: a randomized controlled trial. JAMA.
2004;292(7):821–827. doi:10.1001/jama.292.7.821
15. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression
adjuvant to definitive radiotherapy in prostate carcinoma: longterm results of phase III RTOG 85-31. Int J Radiat Oncol Biol
Phys. 2005;61(5):1285–1290. doi:10.1016/j.ijrobp.2004.08.047
16. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant andro
gen deprivation therapy and external-beam radiotherapy for
locally advanced prostate cancer: long-term results of RTOG
8610. J Clin Oncol. 2008;26(4):585–591. doi:10.1200/JCO.20
07.13.9881
17. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation
with or without long-term androgen suppression for prostate
cancer with high metastatic risk: 10-year results of an EORTC
randomised study. Lancet Oncol. 2010;11(11):1066–1073.
doi:10.1016/S1470-2045(10)70223-0
18. Bolla M, Maingon P, Carrie C, et al. Short androgen suppression
and radiation dose escalation for intermediate- and high-risk
localized prostate cancer: results of EORTC trial 22991. J Clin
Oncol. 2016;34(15):1748–1756. doi:10.1200/JCO.2015.64.8055
19. Nabid A, Carrier N, Vigneault E, et al. A phase III trial of shortterm androgen deprivation therapy in intermediate-risk prostate
cancer treated with radiotherapy. J Clin Oncol. 2015;33
(15_suppl):5019. doi:10.1200/jco.2015.33.15_suppl.5019
20. Morris WJ, Tyldesley S, Rodda S, et al. Androgen suppression
combined with elective nodal and dose escalated radiation therapy
(the ASCENDE-RT trial): an analysis of survival endpoints for a
randomized trial comparing a low-dose-rate brachytherapy boost
to a dose-escalated external beam boost for high- and intermedi
ate-risk prostate cancer. Int J Radiat Oncol. 2017;98(2):275–285.
doi:10.1016/j.ijrobp.2016.11.026
21. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of
radiation therapy oncology group protocol 92-02: a phase iii
trial of the duration of elective androgen deprivation in locally
advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–2504.
doi:10.1200/JCO.2007.14.9021

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

543

Research and Reports in Urology downloaded from https://www.dovepress.com/ by 147.140.233.14 on 22-Dec-2020
For personal use only.

Taylor et al
22. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of
androgen suppression in the treatment of prostate cancer. N Engl J
Med. 2009;12:2516–2527.
23. Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen
suppression before radiotherapy for localized prostate cancer:
radiation therapy oncology group randomized clinical trial 9910.
J Clin Oncol. 2015;33(4):332–339. doi:10.1200/JCO.2014.58.
0662
24. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant
androgen deprivation and radiotherapy for locally advanced pros
tate cancer: 10-year data from the TROG 96.01 randomised trial.
Lancet Oncol. 2011;12(5):451–459. doi:10.1016/S1470-2045(11)
70063-8
25. Zapatero A, Guerrero A, Maldonado X, et al. High-dose radio
therapy with short-term or long-term androgen deprivation in
localised prostate cancer (DART01/05 GICOR): a randomised,
controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–327.
doi:10.1016/S1470-2045(15)70045-8
26. Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation
therapy plus docetaxel and estramustine versus androgen depriva
tion therapy alone for high-risk localised prostate cancer (GETUG
12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16
(7):787–794. doi:10.1016/S1470-2045(15)00011-X
27. Rosenthal SA, Hu C, Sartor O, et al. Effect of chemotherapy with
docetaxel with androgen suppression and radiotherapy for loca
lized high-risk prostate cancer: the randomized phase III NRG
oncology RTOG 0521 trial. J Clin Oncol. 2019;37(14):1159–
1168. doi:10.1200/JCO.18.02158
28. Roach M, Moughan J, Lawton CAF, et al. Sequence of hormonal
therapy and radiotherapy field size in unfavourable, localised
prostate cancer (NRG/RTOG 9413): long-term results of a rando
mised, phase 3 trial. Lancet Oncol. 2018;19(11):1504–1515.
doi:10.1016/S1470-2045(18)30528-X
29. Spratt DE, Vargas HA, Zumsteg ZS, et al. Patterns of lymph node
failure after dose-escalated radiotherapy: implications for
extended pelvic lymph node coverage. Eur Urol. 2017;71
(1):37–43. doi:10.1016/j.eururo.2016.07.043
30. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radio
therapy for pathological T3N0M0 prostate cancer significantly
reduces risk of metastases and improves survival: long-term fol
lowup of a randomized clinical trial. J Urol. 2009;181(3):956–
962. doi:10.1016/j.juro.2008.11.032
31. Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy
versus wait-and-see after radical prostatectomy: 10-year followup of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66
(2):243–250. doi:10.1016/j.eururo.2014.03.011
32. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy
after radical prostatectomy for high-risk prostate cancer: long-term
results of a randomised controlled trial (EORTC trial 22911). Lancet
London Engl. 2012;380(9858):2018-2027. doi:10.1016/S0140-6736
(12)61253-7
33. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen sup
pression plus radiation versus radiation alone for patients with
stage D1/pathologic node-positive adenocarcinoma of the pros
tate: updated results based on national prospective randomized
trial Radiation Therapy Oncology Group 85-31. J Clin Oncol.
2005;23(4):800–807. doi:10.1200/JCO.2005.08.141
34. Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of
a multi-institutional predictive nomogram for salvage radiother
apy after radical prostatectomy. J Clin Oncol. 2016;34(30):3648–
3654. doi:10.1200/JCO.2016.67.9647
35. Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or
without antiandrogen therapy in recurrent prostate cancer. N
Engl J Med. 2017;376(5):417–428. doi:10.1056/NEJMoa1607
529

544

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

Dovepress
36. Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with
or without short-term hormone therapy for rising prostate-specific
antigen concentration after radical prostatectomy (GETUG-AFU
16): a randomised, multicentre, open-label phase 3 trial. Lancet
Oncol. 2016;17(6):747–756. doi:10.1016/S1470-2045(16)00111-X
37. Pollack A, Karrison TG, Balogh AG, et al. Short term androgen
deprivation therapy without or with pelvic lymph node treatment
added to prostate bed only salvage radiotherapy: the NRG oncol
ogy/RTOG 0534 SPPORT trial. Int J Radiat Oncol. 2018;102
(5):1605. doi:10.1016/j.ijrobp.2018.08.052
38. Wallis CJD, Saskin R, Choo R, et al. Surgery versus radiotherapy
for clinically-localized prostate cancer: a systematic review and
meta-analysis. Eur Urol. 2016;70(1):21–30. doi:10.1016/j.eururo.
2015.11.010
39. Roach M, Ceron Lizarraga TL, Lazar AA. Radical prostatectomy
versus radiation and androgen deprivation therapy for clinically
localized prostate cancer: how good is the evidence? Int J Radiat
Oncol. 2015;93(5):1064–1070. doi:10.1016/j.ijrobp.2015.08.005
40. Greenberger BA, Zaorsky NG, Den RB. Comparison of radical
prostatectomy versus radiation and androgen deprivation therapy
strategies as primary treatment for high-risk localized prostate
cancer: a systematic review and meta-analysis. Eur Urol Focus.
2019. doi:10.1016/j.euf.2019.11.007
41. Greenberger BA, Chen VE, Den RB. Combined modality thera
pies for high-risk prostate cancer: narrative review of current
understanding and new directions. Front Oncol. 2019;9. doi:10.
3389/fonc.2019.01273
42. Kishan AU, Cook RR, Ciezki JP, et al. Radical prostatectomy,
external beam radiotherapy, or external beam radiotherapy with
brachytherapy boost and disease progression and mortality in
patients with Gleason score 9–10 prostate cancer. JAMA.
2018;319(9):896–905. doi:10.1001/jama.2018.0587
43. Tilki D, Chen M-H, Wu J, et al. Surgery vs radiotherapy in the
management of biopsy Gleason score 9–10 prostate cancer and
the risk of mortality. JAMA Oncol. 2018. doi:10.1001/jamaoncol.
2018.4836
44. Muralidhar V, Mahal BA, Butler S, et al. Combined external
beam radiation therapy and brachytherapy versus radical prosta
tectomy with adjuvant radiation therapy for Gleason 9–10 pros
tate cancer. J Urol. 2019;202(5):973–978. doi:10.1097/JU.000000
0000000352
45. Lepor H. A review of surgical techniques for radical prostatect
omy. Rev Urol. 2005;7(2):S11–S17.
46. Koch MO, Smith JA. Blood loss during radical retropubic pros
tatectomy: is preoperative autologous blood donation indicated? J
Urol. 1996;156(3):1077–1080. doi:10.1016/S0022-5347(01)657
06-9
47. Lance RS, Freidrichs PA, Kane C, et al. A comparison of radical
retropubic with perineal prostatectomy for localized prostate can
cer within the Uniformed Services Urology Research Group:
comparison of RRP with RPP for prostate cancer. BJU Int.
2001;87(1):61–65. doi:10.1046/j.1464-410x.2001.00023.x
48. Chandrasekar T, Tilki D. Robotic-assisted vs. open radical pros
tatectomy: an update to the never-ending debate. Transl Androl
Urol. 2018;7(S1):S120–S123. doi:10.21037/tau.2017.12.20
49. Dinneen E, Haider A, Allen C, et al. NeuroSAFE robot-assisted
laparoscopic prostatectomy versus standard robot-assisted laparo
scopic prostatectomy for men with localised prostate cancer
(NeuroSAFE PROOF): protocol for a randomised controlled fea
sibility study. BMJ Open. 2019;9(6):e028132. doi:10.1136/bmjo
pen-2018-028132
50. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.
D. anderson randomized dose-escalation trial for prostate cancer.
Int J Radiat Oncol. 2008;70(1):67–74. doi:10.1016/j.ijrobp.2007.
06.054

Research and Reports in Urology 2020:12

Research and Reports in Urology downloaded from https://www.dovepress.com/ by 147.140.233.14 on 22-Dec-2020
For personal use only.

Dovepress
51. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing
conventional-dose with high-dose conformal radiation therapy in
early-stage adenocarcinoma of the prostate: long-term results
from proton radiation oncology group/american college of radi
ology 95-09. J Clin Oncol. 2010;28(7):1106–1111. doi:10.1200/
JCO.2009.25.8475
52. Al-Mamgani A, van Putten WLJ, Heemsbergen WD, et al.
Update of dutch multicenter dose-escalation trial of radiotherapy
for localized prostate cancer. Int J Radiat Oncol. 2008;72(4):980–
988. doi:10.1016/j.ijrobp.2008.02.073
53. Michalski JM, Moughan J, Purdy J, et al. Effect of standard vs
dose-escalated radiation therapy for patients with intermediaterisk prostate cancer: the NRG oncology RTOG 0126 randomized
clinical trial. JAMA Oncol. 2018;4(6):e180039. doi:10.1001/
jamaoncol.2018.0039
54. Roy S, Morgan SC. Hypofractionated radiotherapy for localized
prostate cancer: when and for whom? Curr Urol Rep. 2019;20(9).
doi:10.1007/s11934-019-0918-0
55. Fischer-Valuck BW, Rao YJ, Michalski JM. Intensity-modulated
radiotherapy for prostate cancer. Transl Androl Urol. 2018;7
(3):297–307. doi:10.21037/tau.2017.12.16
56. Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue
contouring guidelines for radiation therapy: a Radiation Therapy
Oncology Group consensus panel atlas. Int J Radiat Oncol.
2012;83(3):e353–e362. doi:10.1016/j.ijrobp.2012.01.023
57. Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG
consensus guidelines for the definition of the clinical target
volume for postoperative conformal radiation therapy for prostate
cancer. Int J Radiat Oncol. 2010;76(2):361–368. doi:10.1016/j.
ijrobp.2009.02.006
58. Afkhami Ardekani M, Ghaffari H. Optimization of prostate bra
chytherapy techniques with polyethylene glycol–based hydrogel
spacers: a systematic review. Brachytherapy. 2020;19(1):13–23.
doi:10.1016/j.brachy.2019.08.009
59. Giesler RB, Miles BJ, Cowen ME, Kattan MW. Assessing quality
of life in men with clinically localized prostate cancer: develop
ment of a new instrument for use in multiple settings. Qual Life
Res. 2000;9(6):645–665.
60. Sosnowski R. Basic issues concerning health-related quality of life.
Cent Eur J Urol. 2017;70(2):206–211. doi:10.5173/ceju.2017.923
61. Gandaglia G, Bray F, Cooperberg MR, et al. Prostate cancer
registries: current status and future directions. Eur Urol.
2016;69(6):998–1012. doi:10.1016/j.eururo.2015.05.046
62. Soni PD, Hartman HE, Dess RT, et al. Comparison of populationbased observational studies with randomized trials in oncology. J
Clin Oncol. 2019;37(14):1209–1216. doi:10.1200/JCO.18.01074
63. Resnick MJ, Koyama T, Fan K-H, et al. Long-term functional
outcomes after treatment for localized prostate cancer. N Engl J
Med. 2013;368(5):436–445. doi:10.1056/NEJMoa1209978
64. Barocas DA, Alvarez J, Resnick MJ, et al. Association between
radiation therapy, surgery, or observation for localized prostate
cancer and patient-reported outcomes after 3 years. JAMA.
2017;317(11):1126–1140. doi:10.1001/jama.2017.1704
65. Chen RC, Basak R, Meyer A-M, et al. Association between
choice of radical prostatectomy, external beam radiotherapy, bra
chytherapy, or active surveillance and patient-reported quality of
life among men with localized prostate cancer. JAMA. 2017;317
(11):1141–1150. doi:10.1001/jama.2017.1652
66. Whiting PF, Moore THM, Jameson CM, et al. Symptomatic and
quality-of-life outcomes after treatment for clinically localised
prostate cancer: a systematic review. BJU Int. 2016;118(2):193–
204. doi:10.1111/bju.13499
67. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported out
comes after monitoring, surgery, or radiotherapy for prostate
cancer. N Engl J Med. 2016;375(15):1425–1437. doi:10.1056/
NEJMoa1606221

Research and Reports in Urology 2020:12

Taylor et al
68. Stranne J, Brasso K, Brennhovd B, et al. SPCG-15: a prospective
randomized study comparing primary radical prostatectomy and
primary radiotherapy plus androgen deprivation therapy for
locally advanced prostate cancer. Scand J Urol. 2018;52(5–
6):313–320. doi:10.1080/21681805.2018.1520295
69. Wolff D, Stieler F, Welzel G, et al. Volumetric modulated arc
therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and
3D-conformal RT for treatment of prostate cancer. Radiother
Oncol. 2009;93(2):226–233. doi:10.1016/j.radonc.2009.08.011
70. Lennernäs B, Majumder K, Damber J-E, et al. Radical prostatect
omy versus high-dose irradiation in localized/locally advanced
prostate cancer: a Swedish multicenter randomized trial with
patient-reported outcomes. Acta Oncol. 2015;54(6):875–881.
doi:10.3109/0284186X.2014.974827
71. Crook JM, Gomez-Iturriaga A, Wallace K, et al. Comparison of
health-related quality of life 5 years after SPIRIT: surgical pros
tatectomy versus interstitial radiation intervention trial. J Clin
Oncol. 2010. doi:10.1200/JCO.2010.31.7305
72. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E. Radical
retropubic prostatectomy versus brachytherapy for low-risk pro
static cancer: a prospective study. World J Urol. 2009;27(5):607–
612. doi:10.1007/s00345-009-0418-9
73. Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an
analysis of treatment-related morbidity for a randomized trial
comparing a low-dose-rate brachytherapy boost with a dose-esca
lated external beam boost for high- and intermediate-risk prostate
cancer. Int J Radiat Oncol. 2017;98(2):286–295. doi:10.1016/j.
ijrobp.2017.01.008
74. Hoffman KE, Penson DF, Zhao Z, et al. Patient-reported out
comes through 5 years for active surveillance, surgery, bra
chytherapy, or external beam radiation with or without androgen
deprivation therapy for localized prostate cancer. JAMA.
2020;323(2):149. doi:10.1001/jama.2019.20675
75. Dacal K, Sereika SM, Greenspan SL. Quality of life in prostate
cancer patients taking androgen deprivation therapy: quality of
life in men with prostate cancer. J Am Geriatr Soc. 2006;54
(1):85–90. doi:10.1111/j.1532-5415.2005.00567.x
76. Cheung AS, de Rooy C, Hoermann R, Lim Joon D, Zajac JD,
Grossmann M. Quality of life decrements in men with prostate
cancer undergoing androgen deprivation therapy. Clin Endocrinol
(Oxf). 2017;86(3):388–394. doi:10.1111/cen.13249
77. Gay HA, Sanda MG, Liu J, et al. External beam radiation therapy
or brachytherapy with or without short-course neoadjuvant andro
gen deprivation therapy: results of a multicenter, prospective
study of quality of life. Int J Radiat Oncol. 2017;98(2):304–
317. doi:10.1016/j.ijrobp.2017.02.019
78. Jenkins DK, Swanson GP, Jhavar SG, Wagner KR, Ha CS, Chen W.
Worsening of Urinary Quality of Life (QOL) is seen in patients
receiving delayed post-prostatectomy radiation. Int J Radiat Oncol.
2018;102(3):e121. doi:10.1016/j.ijrobp.2018.07.325
79. Melotek JM, Liao C, Liauw SL, Gao X. Quality of life after postprostatectomy intensity modulated radiation therapy: pelvic nodal
irradiation is not associated with worse bladder, bowel, or sexual
outcomes. Gao X, ed. PLoS One. 2015;10(10):e0141639.
doi:10.1371/journal.pone.0141639
80. van Stam M-A, Aaronson NK, Pos FJ, et al. The effect of salvage
radiotherapy and its timing on the health-related quality of life of
prostate cancer patients. Eur Urol. 2016;70(5):751–757.
doi:10.1016/j.eururo.2016.03.010
81. Eastham James A, Kattan Michael W, Eamonn R, et al. Risk factors
for urinary incontinence after radical prostatectomy. J Urol.
1996;156(5):1707–1713. doi:10.1016/S0022-5347(01)65488-0
82. Gousse Angelo E, Shahar M, Marie-May L, Fishman Irving J.
Artificial urinary sphincter for post-radical prostatectomy urinary
incontinence: long-term subjective results. J Urol. 2001;166
(5):1755–1758. doi:10.1016/S0022-5347(05)65668-6

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

545

Dovepress

Research and Reports in Urology downloaded from https://www.dovepress.com/ by 147.140.233.14 on 22-Dec-2020
For personal use only.

Taylor et al
83. Rehder P, Gozzi C. Transobturator sling suspension for male
urinary incontinence including post-radical prostatectomy. Eur
Urol. 2007;52(3):860–867. doi:10.1016/j.eururo.2007.01.110
84. Burgio Kathryn L, Stutzman Ray E, Engel Bernard T. Behavioral
training for post-prostatectomy urinary incontinence. J Urol.
1989;141(2):303–306. doi:10.1016/S0022-5347(17)40747-6
85. Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev
Urol. 2010;7(4):206–214. doi:10.1038/nrurol.2010.23
86. Lee S-I, Park Y-A, Sohn S-K. Formalin application for the treat
ment of radiation-induced hemorrhagic proctitis. Yonsei Med J.
2007;48(1):97–100. doi:10.3349/ymj.2007.48.1.97
87. Seow-Choen F, Goh H-S, Eu K-W, Ho Y-H, Tay S-K. A simple
and effective treatment for hemorrhagic radiation proctitis using
formalin. Dis Colon Rectum. 1993;36(2):135–138. doi:10.1007/
BF02051168
88. Tam W, Moore J, Schoeman M. Treatment of radiation proctitis
with argon plasma coagulation. Endoscopy. 2000;32(9):667–672.
doi:10.1055/s-2000-9020
89. Zhou C, Adler DC, Becker L, et al. Effective treatment of chronic
radiation proctitis using radiofrequency ablation. Therap Adv
Gastroenterol. 2009;2(3):149–156. doi:10.1177/1756283X081
03341
90. Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are
effective in short-term treatment of chronic radiation proctitis. Dis
Colon Rectum. 1999;42(6):788–795. doi:10.1007/BF02236937
91. Corman JM, McCLURE D, Pritchett R, Kozlowski P, Hampson
NB. Treatment of radiation induced hemorrhagic cystitis with
hyperbaric oxygen. J Urol. 2003;169(6):2200–2202. doi:10.109
7/01.ju.0000063640.41307.c9
92. Woo TCS, Joseph D, Oxer H. Hyperbaric oxygen treatment for
radiation proctitis. Int J Radiat Oncol. 1997;38(3):619–622.
doi:10.1016/S0360-3016(97)00017-5
93. Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after
radiotherapy for prostate cancer: a review. Int J Radiat Oncol.
2002;52(3):681–693. doi:10.1016/S0360-3016(01)02727-4
94. Chung E, Brock G. Sexual rehabilitation and cancer survivorship:
a state of art review of current literature and management strate
gies in male sexual dysfunction among prostate cancer survivors.
J Sex Med. 2013;10(S1):102–111. doi:10.1111/j.1743-6109.2012.
03005.x
95. Zelefsky Michael J, Daniel S, Dunn BR, et al. Prophylactic
sildenafil citrate improves select aspects of sexual function in
men treated with radiotherapy for prostate cancer. J Urol.
2014;192(3):868–874. doi:10.1016/j.juro.2014.02.097

96. Mazzola C, Mulhall JP. Penile rehabilitation after prostate cancer
treatment: outcomes and practical algorithm. Urol Clin North Am.
2011;38(2):105–118. doi:10.1016/j.ucl.2011.03.002
97. Dubocq FM, Bianco FJ, Maralani SJ, Forman JD, Dhabuwala
CB. Outcome analysis of penile implant surgery after external
beam radiation for prostate cancer. J Urol. 1997;158(5):1787–
1790. doi:10.1016/S0022-5347(01)64129-6
98. Pahlajani G, Raina R, Jones S, Ali M, Zippe C. Vacuum erection
devices revisited: its emerging role in the treatment of erectile
dysfunction and early penile rehabilitation following prostate
cancer therapy. J Sex Med. 2012;9(4):1182–1189. doi:10.1111/
j.1743-6109.2010.01881.x
99. Cormie P, Newton RU, Taaffe DR, Spry N, Galvão DA. Exercise
therapy for sexual dysfunction after prostate cancer. Nat Rev Urol
London. 2013;10(12):731–736. doi:10.1038/nrurol.2013.206
100. Badr H, Taylor CLC. Sexual dysfunction and spousal communi
cation in couples coping with prostate cancer. Psychooncology.
2009;18(7):735–746. doi:10.1002/pon.1449
101. Delobel J-B, Gnep K, Ospina JD, et al. Nomogram to predict
rectal toxicity following prostate cancer radiotherapy. Sung S-Y,
ed. PLoS One. 2017;12(6):e0179845. doi:10.1371/journal.pone.
0179845
102. Valdagni R, Rancati T, Fiorino C, et al. Development of a set of
nomograms to predict acute lower gastrointestinal toxicity for
prostate cancer 3D-CRT. Int J Radiat Oncol. 2008;71(4):1065–
1073. doi:10.1016/j.ijrobp.2007.11.037
103. Valdagni R, Kattan MW, Rancati T, et al. Is it time to tailor the
prediction of radio-induced toxicity in prostate cancer patients?
Building the first set of nomograms for late rectal syndrome. Int J
Radiat Oncol. 2012;82(5):1957–1966. doi:10.1016/j.ijrobp.2011.
03.028
104. Mathieu R, Arango JDO, Beckendorf V, et al. Nomograms to
predict late urinary toxicity after prostate cancer radiotherapy.
World J Urol. 2014;32(3):743–751. doi:10.1007/s00345-013-11
46-8
105. Montie JE. Counseling the patient with localized prostate cancer.
Urology. 1994;43:36–40. doi:10.1016/0090-4295(94)90216-X
106. Valicenti RK, Gomella LG, El-Gabry EA, et al. The multidisci
plinary clinic approach to prostate cancer counseling and treat
ment. Semin Urol Oncol. 2000;18(3):188–191.
107. Gomella LG, Lin J, Hoffman-Censits J, et al. Enhancing prostate
cancer care through the multidisciplinary clinic approach: a 15year experience. J Oncol Pract. 2010;6(6):e5–e10. doi:10.1200/
JOP.2010.000071

Dovepress

Research and Reports in Urology

Publish your work in this journal
Research and Reports in Urology is an international, peer-reviewed,
open access journal publishing original research, reports, editorials,
reviews and commentaries on all aspects of adult and pediatric
urology in the clinic and laboratory including the following topics:
Pathology, pathophysiology of urological disease; Investigation and

treatment of urological disease; Pharmacology of drugs used for the
treatment of urological disease. The manuscript management system
is completely online and includes a very quick and fair peer-review
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/research-and-reports-in-urology-journal

546

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

Research and Reports in Urology 2020:12

